Estimated rate of thromboxane secretion into the circulation of normal humans
about
11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulationPlatelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery diseaseAspirin resistance: an evaluation of current evidence and measurement methodsCyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outsAntiplatelet drugsAbnormalities in the biosynthesis of thromboxane A2 and prostacyclin in children with cyanotic congenital heart diseaseBiosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.Time course change of COX2-PGI2/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus.Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension.Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapyBiosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgammaAcute phase response in patients undergoing lumbar spinal surgery: modulation by perioperative treatment with naproxen and famotidineEndothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.Urinary 11-Dehydro-Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) StudyProstaglandins, the kidney, and hypertension.A contemporary viewpoint on 'aspirin resistance'.Antiplatelet therapy: aspirin resistance and all that jazz!Advances in monitoring of aspirin therapy.Aspirin resistance: a clinical review focused on the most common cause, noncompliance.Measurements of the in vivo synthesis of thromboxane and prostacyclin in humans.Variations in white blood count, thromboxane B2 levels and hematocrit in chronic venous hypertension.A new target for squamous cell skin cancer?Determination of misoprostol free acid in human breast milk and serum by gas chromatography/negative ion chemical ionization tandem mass spectrometry.The effect of selected pre-analytical phase variables on plasma thromboxane A₂ measurements in humans.Urinary excretion of lipid mediators in response to repeated eucapnic voluntary hyperpnea in asthmatic subjects.Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment.Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group.The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting.Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge and in vivo urinary thromboxane production in healthy male subjectsEffects of thermosensitive poly(N-isopropylacrylamide) on blood coagulationIsoform-Specific Compensation of Cyclooxygenase (Ptgs) Genes during Implantation and Late-Stage Pregnancy
P2860
Q24630260-D6E389AC-F730-44D4-938D-7AF3FA9CC460Q27027247-FA092C52-4F29-4B52-91C1-C680F25103ABQ28183220-7EEF5193-A0BC-49A2-8B25-7AFEDF201225Q28186050-E4F1EEBE-596F-4BDD-A80C-893A49B70FF4Q28194430-8D4E240F-C145-4A5E-9B82-8D772A03FFC6Q33612283-3A1D55D1-A608-4EC8-972D-09DD3729EDACQ34285416-E5434339-886D-4D00-AC75-7EAED573B73CQ34536091-7DE07AA8-AB33-4DED-947E-4479EFD789EEQ34558658-162024F7-C7D1-4A83-A2D6-5B69F2F0AC45Q35066042-284B148D-5549-4C4C-97AF-EF897938774CQ35373624-0F9990F8-0CFA-4020-A784-FA62DAA43065Q35919761-C09C54D4-1963-48ED-A429-F52153BC29B2Q36307990-2A40A527-682E-4B49-A1CE-6F6D64449F1FQ36965292-B2B9F830-21B9-47A2-B803-C3947A46B94DQ37240415-64B41F9E-4094-4968-9DB3-616FFCBC1C74Q37971323-64562436-B92F-4B30-AC9C-E28268B92267Q37989558-5B6583CF-CCDE-4DE9-BECA-7340BB3037C5Q38023196-5AE07357-ED64-4595-85DF-F358F209F40EQ38032895-5D4B3753-5B6E-449E-9DF1-4200A604F1FBQ38132148-2540614D-5474-4445-AC57-415D85096952Q39550266-FED07A55-7B4E-4D97-A944-50EE50E4F366Q40829916-257BF98F-D3A2-447B-802A-E3C980647EC9Q43099655-D6D5D0C4-CB83-404D-862F-6B722B5C34C4Q44149826-078CA6B3-D5E1-4BBE-BF64-6CBDF6F68AE0Q45100805-542A6D25-1B7B-4598-9FFF-2297D83E6D91Q47961399-90F06B77-95BD-4C21-A015-7FFF9380A596Q49960507-E440DF55-9CF7-40E6-89CC-102D3A546E98Q50916767-4DA9D07F-901A-4206-ACB7-3C58F1FFAA50Q55284640-AAEE009C-ED68-4E26-B47C-16929A0E771CQ57100496-D6A5170C-C1E3-4E41-9A52-6D68D039D631Q57367552-BE080EA3-5531-406B-98FF-80197E976957Q58782993-6522AD28-2CDE-45B8-B761-584617BA2AD1
P2860
Estimated rate of thromboxane secretion into the circulation of normal humans
description
1986 nî lūn-bûn
@nan
1986 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
name
Estimated rate of thromboxane secretion into the circulation of normal humans
@ast
Estimated rate of thromboxane secretion into the circulation of normal humans
@en
Estimated rate of thromboxane secretion into the circulation of normal humans
@nl
type
label
Estimated rate of thromboxane secretion into the circulation of normal humans
@ast
Estimated rate of thromboxane secretion into the circulation of normal humans
@en
Estimated rate of thromboxane secretion into the circulation of normal humans
@nl
prefLabel
Estimated rate of thromboxane secretion into the circulation of normal humans
@ast
Estimated rate of thromboxane secretion into the circulation of normal humans
@en
Estimated rate of thromboxane secretion into the circulation of normal humans
@nl
P2093
P2860
P356
P1476
Estimated rate of thromboxane secretion into the circulation of normal humans
@en
P2093
A Pierucci
F Pugliese
G A FitzGerald
G Ciabattoni
P2860
P304
P356
10.1172/JCI112341
P407
P577
1986-02-01T00:00:00Z